HLA-derived peptides as novel immunosuppressives

• Published in: Nephrology, dialysis, transplantation Vol. 12; no. 5; pp. 865 - 868
• Main Authors: Krensky, A M, Clayberger, C
• Format: Journal Article
• Language: English
• Published: England 01.05.1997
• Subjects: Graft Survival - drug effects; HLA Antigens - chemistry; HLA Antigens - pharmacology; Humans; Immunosuppressive Agents - chemistry; Immunosuppressive Agents - pharmacology; Models, Molecular; Molecular Structure; Peptides - chemistry; Peptides - pharmacology; Transplantation Immunology
• ISSN: 0931-0509; 1460-2385
• DOI: 10.1093/ndt/12.5.865

Over the past decade the use of synthetic peptides corresponding to linear sequences of HLA molecules has progressed from a concept to a reality. These peptides are currently being evaluated in clinical trials. In animal models these peptides, given over 1 week with cyclosporin alone, induced long-term immunological tolerance (Figure 3). They may similarly induce tolerance in humans. The next major hurdle for such tolerogenic drugs, however, is to prove efficacy in clinical circumstances. Many of the drugs used to treat transplant patients today (steroids, cyclosporin, azathioprine, mycophenolate mofetil) may actually inhibit the 'active' processes of induction and maintenance of immunological tolerance. Demonstration that new drugs induce tolerance will require efficacy studies in other immune-mediated diseases in which monotherapy is feasible (such as psoriasis), before further advances can be made in the induction of transplant tolerance. In addition, rapid assays of rejection must be developed in order to reverse tolerance induction failures without graft damage or loss. Lastly, it will require heroic physicians, surgeons, and patients to make immunological tolerance a reproducible clinical reality.